RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells.

PURPOSE: Phase II trial to study the effectiveness of busulfan and melphalan followed by donor bone marrow transplantation in treating patients who have advanced hematologic cancer.

Condition	Treatment or Intervention	Phase
acute leukemia atypical chronic myeloid leukemia chronic leukemia Graft Versus Host Disease myelodysplastic and myeloproliferative disease	Drug: busulfan  Drug: melphalan  Drug: methotrexate  Drug: tacrolimus  Procedure: allogeneic bone marrow transplantation  Procedure: biological response modifier therapy  Procedure: bone marrow ablation with stem cell support  Procedure: bone marrow transplantation  Procedure: chemotherapy  Procedure: graft versus host disease prophylaxis/therapy  Procedure: supportive care/therapy	Phase II

Further Study Details: 

OBJECTIVES:

• Determine the antileukemic potential of busulfan and melphalan prior to allogeneic bone marrow transplantation in patients with advanced or high-risk hematologic malignancy.
• Determine the incidence of transplantation-related morbidity and mortality in patients treated with this regimen.
• Determine the incidence of acute and chronic graft-versus-host disease in patients treated with this regimen.

OUTLINE: Patients receive cytoreductive chemotherapy comprising busulfan IV over 2 hours every 6 hours for a total of 16 doses on days -8 to -5 and melphalan IV over 30 minutes on days -4 to -2. Patients undergo T-cell replete allogeneic bone marrow transplantation on day 0. For graft-versus-host disease prophylaxis, patients receive tacrolimus IV continuously or every 12 hours beginning on day -1 and continuing for 50 days to 6 months followed by a taper. Once oral medications are tolerated, patients switch to oral tacrolimus every 12 hours. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Patients are followed weekly through day 100, every 6 weeks for 3 months, every 3 months for 1 year, and then every 3-6 months for 6 months.

PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 3 years.

Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of one of the following:
• Infant leukemia
• Acute lymphoblastic leukemia in 3rd or greater remission or relapse
• Undifferentiated or biphenotypic leukemia in 2nd or greater remission or relapse
• Juvenile chronic myelogenous leukemia (CML)
• Acute myelogenous leukemia (AML) in 3rd or greater remission or relapse
• Primary advanced myelodysplastic syndrome (MDS) excluding refractory anemia (RA) and RA with ringed sideroblasts
• Therapy-related MDS of any stage or AML
• CML in 2nd or greater chronic phase, accelerated, or blastic phase
• Acute leukemia, CML, or MDS but unable to tolerate total body irradiation (TBI) due to potential neurotoxicity (prior TBI, prior local radiotherapy,or under 2 years of age)
• No active CNS disease
• Related or unrelated bone marrow donor matched at HLA-A, B, and DR beta 1

PATIENT CHARACTERISTICS: Age:

• Under 60 (over 60 considered on case-by-case basis)

Performance status:

• Karnofsky 70-100%
• Lansky 70-100%

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• AST and ALT less than 2 times upper limit of normal
• Bilirubin less than 1.5 mg/dL unless liver is involved with disease

Renal:

• Creatinine normal
• Creatinine clearance greater than 60 mL/min

Cardiovascular:

• Asymptomatic with no prior risk factors OR
• LVEF greater than 50% if symptomatic

Pulmonary:

• Asymptomatic with no prior risk factors OR
• Diffusion capacity greater than 50% predicted (corrected for hemoglobin) if symptomatic

Other:

• No active uncontrolled viral, bacterial, or fungal infection
• Not pregnant or nursing
• Negative pregnancy test
• HIV negative

PRIOR CONCURRENT THERAPY: Biologic therapy:

• More than 6 months since prior allogeneic or autologous stem cell transplantation

Chemotherapy:

• Not specified

Endocrine therapy:

• Not specified

Radiotherapy:

• See Disease Characteristics

Surgery:

• Not specified

New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States; Recruiting

Study chairs or principal investigators

Trudy Small, MD,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

Study ID Numbers:  CDR0000068546; MSKCC-00126; NCI-H01-0070; NCT00014469
Record last reviewed:  December 2001
Last Updated:  December 6, 2004
Record first received:  April 10, 2001
ClinicalTrials.gov Identifier:  NCT00014469
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08